Kodiak Sciences (NASDAQ:KOD – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.
KOD has been the subject of several other reports. The Goldman Sachs Group assumed coverage on Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target for the company. Weiss Ratings downgraded Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. Jefferies Financial Group restated a “buy” rating and issued a $112.00 price objective on shares of Kodiak Sciences in a research report on Monday, September 28th. Lifesci Capital raised their price objective on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Finally, UBS Group lifted their target price on shares of Kodiak Sciences from $120.00 to $150.00 and gave the company a “buy” rating in a report on Friday, November 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $117.86.
Check Out Our Latest Report on KOD
Kodiak Sciences Trading Down 0.7%
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.01. On average, research analysts forecast that Kodiak Sciences will post -4.05 earnings per share for the current year.
Insiders Place Their Bets
In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 807,840 shares of the company’s stock in a transaction on Monday, September 28th. The shares were bought at an average cost of $72.57 per share, with a total value of $58,624,948.80. Following the completion of the acquisition, the director owned 19,121,134 shares in the company, valued at approximately $1,387,620,694.38. This trade represents a 4.41% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders bought 2,188,845 shares of company stock valued at $181,326,862. Corporate insiders own 44.40% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Ghisallo Capital Management LLC grew its stake in Kodiak Sciences by 33.3% in the 3rd quarter. Ghisallo Capital Management LLC now owns 200,000 shares of the company’s stock valued at $18,960,000 after acquiring an additional 50,000 shares during the period. Baker BROS. Advisors LP raised its position in Kodiak Sciences by 9.7% during the third quarter. Baker BROS. Advisors LP now owns 21,860,941 shares of the company’s stock worth $2,072,417,000 after acquiring an additional 1,941,755 shares during the period. Soleus Capital Management L.P. acquired a new position in Kodiak Sciences during the third quarter worth $27,204,000. Bellevue Group AG purchased a new position in Kodiak Sciences during the third quarter valued at $43,648,000. Finally, Cetera Investment Advisers purchased a new position in Kodiak Sciences during the third quarter valued at $231,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Kodiak Sciences Company Profile
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.
See Also
- Five stocks we like better than Kodiak Sciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
